Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Hisataka Fujimoto, Shintaro Ochi, Yasushi Inoue & Junichi Kiryu. (2022) Upper Eyelid Meibomian Gland Dysfunction is a Risk Factor for Dry Eye Symptoms Following Cataract Surgery in the Early Phase. Clinical Ophthalmology 16, pages 293-302.
Read now
Read now
Articles from other publishers (12)
Ho Seok Chung, Ye Eun Han, Hun Lee, Jae Yong Kim & Hungwon Tchah. (2022) Intense pulsed light treatment of the upper and lower eyelids in patients with moderate-to-severe meibomian gland dysfunction. International Ophthalmology 43:1, pages 73-82.
Crossref
Crossref
Ho Seok Chung, Jae Won Rhim & Jin Hyoung Park. (2022) Combination treatment with intense pulsed light, thermal pulsation (LipiFlow), and meibomian gland expression for refractory meibomian gland dysfunction. International Ophthalmology 42:11, pages 3311-3319.
Crossref
Crossref
Qing Zhang, Hongda ZhangGuanghao QinYi Wu, Yilin SongLanting YangSile YuXingru HeJonathan E. MooreSalissou MoutariChristoph PalmeLing XuWei HeEmmanuel Eric Pazo. (2022) Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study. Journal of Ocular Pharmacology and Therapeutics 38:2, pages 133-140.
Crossref
Crossref
Yue Guo, Jun Young Ha, He Long Piao, Mi Sun Sung & Sang Woo Park. (2020) The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study. BMC Ophthalmology 20:1.
Crossref
Crossref
Ikhyun Jun, Seonghee Choi, Geun Young Lee, Young Joon Choi, Hyung Keun Lee, Eung Kweon Kim, Kyoung Yul Seo & Tae-im Kim. (2019) Effects of Preservative-free 3% Diquafosol in Patients with Pre-existing Dry Eye Disease after Cataract Surgery: A Randomized Clinical Trial. Scientific Reports 9:1.
Crossref
Crossref
Maria Markoulli & Alex Hui. (2019) Emerging targets of inflammation and tear secretion in dry eye disease. Drug Discovery Today 24:8, pages 1427-1432.
Crossref
Crossref
Shima Fukuoka & Reiko Arita. (2019) Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study. Scientific Reports 9:1.
Crossref
Crossref
Yuri Sakane, Masahiko Yamaguchi & Atsushi Shiraishi. (2019) Retrospective Observational Study on Rebamipide Ophthalmic Suspension on Quality of Life of Dry Eye Disease Patients. Journal of Ophthalmology 2019, pages 1-8.
Crossref
Crossref
Mihir Shah, Sara Cabrera-Ghayouri, Lori-Ann Christie, Katherine S. Held & Veena Viswanath. (2019) Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development. Pharmaceutical Research 36:4.
Crossref
Crossref
Kiyeun Nam, Hyun Jung Kim & Aeri Yoo. (2019) Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials. Ophthalmic Research 61:4, pages 188-198.
Crossref
Crossref
Shiro Amano. (2018) Meibomian Gland Dysfunction: Recent Progress Worldwide and in Japan. Investigative Opthalmology & Visual Science 59:14, pages DES87.
Crossref
Crossref
Keisuke Ikeda, Cem Simsek, Takashi Kojima, Kazunari Higa, Motoko Kawashima, Murat Dogru, Takahiko Shimizu, Kazuo Tsubota & Jun Shimazaki. (2018) The effects of 3% diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice. Graefe's Archive for Clinical and Experimental Ophthalmology 256:4, pages 739-750.
Crossref
Crossref